Jazz Pharmaceuticals PLC (JAZZ) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Jazz Pharmaceuticals PLC, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track JAZZ live on Mooboard →

Later12

  • Dec 31, 2026
    Jazz Pharmaceuticals PLC(JAZZ)Phase 2/3 readout
    Zanidatamab · Phase 2 · Breast Cancer; Gastric Cancer
    NCT06695845: A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors. Primary completion 2026-12-31 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 23, 2027
    Jazz Pharmaceuticals PLC(JAZZ)Phase 2/3 readout
    Xywav · Phase 3 · Narcolepsy; Idiopathic Hypersomnia
    NCT07625280: A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH. Primary completion 2027-12-23 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 1, 2028
    Jazz Pharmaceuticals PLC(JAZZ)Phase 2/3 readout
    Zanidatamab · Phase 2 · HER2-positive Breast Cancer; Breast Cancer
    NCT07102381: A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer. Primary completion 2028-01-01 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 28, 2028
    Jazz Pharmaceuticals PLC(JAZZ)Phase 2/3 readout
    Lurbinectedin · Phase 1 / Phase 2 · Refractory Ewing Sarcoma; Relapsed Ewing Sarcoma
    NCT05734066: Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma. Primary completion 2028-01-28 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 31, 2028
    Jazz Pharmaceuticals PLC(JAZZ)Phase 2/3 readout
    Lurbinectedin · Phase 2 · Extensive-stage Small-cell Lung Cancer
    NCT07459634: A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC. Primary completion 2028-01-31 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 28, 2028
    Jazz Pharmaceuticals PLC(JAZZ)Phase 2/3 readout
    Zanidatamab · Phase 3 · Metastatic HER2-positive Breast Cancer
    NCT06435429: A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer. Primary completion 2028-04-28 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 2028
    Jazz Pharmaceuticals PLC(JAZZ)Phase 2/3 readout
    Dordaviprone (ONC201) · Phase 3 · H3 K27M; Glioma
    NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study). Primary completion 2028-06 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Aug 1, 2028
    Jazz Pharmaceuticals PLC(JAZZ)Phase 2/3 readout
    JZP926 capsule · Phase 2 / Phase 3 · Juvenile Myoclonic Epilepsy
    NCT07723963: A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy. Primary completion 2028-08-01 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 25, 2028
    Jazz Pharmaceuticals PLC(JAZZ)Phase 2/3 readout
    JZP3507 · Phase 2 · Meningioma
    NCT07533942: A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma. Primary completion 2028-10-25 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 1, 2028
    Jazz Pharmaceuticals PLC(JAZZ)Phase 2/3 readout
    Zanidatamab · Phase 3 · Biliary Tract Cancer
    NCT06282575: Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer. Primary completion 2028-12-01 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 15, 2028
    Jazz Pharmaceuticals PLC(JAZZ)Phase 2/3 readout
    ONC206 · Phase 2 · Advanced Pheochromocytoma and Paraganglioma; PCPG
    NCT07282587: Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma. Primary completion 2028-12-15 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 4, 2029
    Jazz Pharmaceuticals PLC(JAZZ)Phase 2/3 readout
    CBD-OS · Phase 3 · Developmental and Epileptic Encephalopathy (DEE)
    NCT07723976: A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE. Primary completion 2029-09-04 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗

How Jazz Pharmaceuticals PLC has moved — past-year price reactions

How binary is JAZZ? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

1.1%
typical day (1Y)
2
±10% days
36.6%
annualized vol
250
trading days
Largest single-day moves
  • +20.6%2025-11-17no matched headline
  • +13.2%2026-02-25no matched headline
  • +7.7%2026-05-06no matched headline
  • +6.1%2025-11-18no matched headline
  • -5.4%2026-01-08no matched headline
  • +5.2%2026-01-14no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

Jazz Pharmaceuticals PLC — active clinical pipeline

Jazz Pharmaceuticals PLC's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

13 assets20 programsPh1 5Ph2 6Ph3 7· 2 post-marketing (Ph4)
AreasOncologyNeuroscienceOther
ZanidatamabOncology · HER2
Phase 2
Breast CancerHER2-positive Breast Cancer
Phase 3
Biliary Tract CancerGastric NeoplasmsMetastatic HER2-positive Breast Cancer
CBD-OSNeuroscience
Phase 1
Focal Seizures
Phase 3
Developmental and Epileptic Encephalopathy (DEE)
Dordaviprone (ONC201)Other
Phase 3
H3 K27M
JZP926 capsuleNeuroscience
Phase 3
Juvenile Myoclonic Epilepsy
XywavNeuroscience
Phase 3
Narcolepsy
LurbinectedinOncology · DNA
Phase 2
Extensive-stage Small-cell Lung CancerRefractory Ewing Sarcoma
ONC206Oncology
Phase 1
Central Nervous System Neoplasms
Phase 2
Advanced Pheochromocytoma and Paraganglioma
JZP3507Other
Phase 2
Meningioma
JZP047Other
Phase 1
Healthy volunteers
JZP815Oncology
Phase 1
Advanced Cancer
JZP898Oncology
Phase 1
Advanced Solid Tumor

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

See the full biopharma catalyst calendar across all covered companies.